<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416179</url>
  </required_header>
  <id_info>
    <org_study_id>B1371019</org_study_id>
    <secondary_id>2017-002822-19</secondary_id>
    <secondary_id>BRIGHT</secondary_id>
    <secondary_id>BRIGHT AML1019</secondary_id>
    <nct_id>NCT03416179</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <acronym>BRIGHT AML1019</acronym>
  <official_title>A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glasdegib is being studied in combination with azacitidine for the treatment of adult&#xD;
      patients with previously untreated acute myeloid leukemia (AML) who are not candidates for&#xD;
      intensive induction chemotherapy (Non-intensive AML population).&#xD;
&#xD;
      Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment&#xD;
      of adult patients with previously untreated acute myeloid leukemia (Intensive AML&#xD;
      population).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two separate registration trials conducted under one protocol number are proposed to&#xD;
      adequately and independently evaluate the addition of glasdegib in intensive and&#xD;
      non-intensive chemotherapy populations. Each study will have an experimental treatment arm&#xD;
      and a placebo arm. Endpoints are the same for each study except where specifically indicated.&#xD;
&#xD;
      Assignment to the Intensive Study or the Non-Intensive Study will be made by the Investigator&#xD;
      based on the 2017 European LeukemiaNet (ELN) recommendations.&#xD;
&#xD;
      Study B1371019 is a randomized (1:1), double-blind, multi-center, placebo controlled study of&#xD;
      chemotherapy in combination with glasdegib versus chemotherapy in combination with placebo in&#xD;
      adult patients with previously untreated AML.&#xD;
&#xD;
      Glasdegib is being studied in combination with azacitidine for the treatment of adult&#xD;
      patients with previously untreated acute myeloid leukemia (AML) who are not candidates for&#xD;
      intensive induction chemotherapy (Non-intensive AML population).&#xD;
&#xD;
      Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment&#xD;
      of adult patients with previously untreated acute myeloid leukemia (Intensive AML&#xD;
      population).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">December 13, 2022</completion_date>
  <primary_completion_date type="Actual">June 5, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, multi-center, placebo controlled study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intensive Study: Overall Survival (OS)</measure>
    <time_frame>Baseline up to 25 months</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-intensive Study: Overall Survival (OS)</measure>
    <time_frame>Baseline up to 25 months</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (DASI-AML/MDS) Questionnaire</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (DASI-AML/MDS) Questionnaire</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Percentage of Participants With Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Percentage of Participants With Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Percentage of Participants With Complete Remission (CR) Including Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Percentage of Participants With Partial Remission (PR)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Percentage of Participants With Partial Remission (PR)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Duration of Response</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Duration of Response</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Time to Response</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Event-free Survival</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Event-free Survival</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Participants Global Impression of Symptoms (PGIS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Participants Global Impression of Symptoms (PGIS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Participants Global Impression of Change (PGIC)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Participants Global Impression of Change (PGIC)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Number of Participants With Laboratory Abnormalities Graded by NCI CTCAE v.4.03</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Number of Participants With Laboratory Abnormalities Graded by NCI CTCAE v.4.03</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib</measure>
    <time_frame>1 and 4 hour post dose on Day 1 in first induction therapy; pre-dose, 1, and 4 hours post dose on day 1 in consolidation phase cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib</measure>
    <time_frame>Pre-dose, 1 and 4 hour post dose on Day 1 and 15 of cycle 1; pre-dose, 1 and 4 hour post dose on day 1 of cycle 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Study: QTc Interval</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-intensive Study: QTc Interval</measure>
    <time_frame>Baseline up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">730</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Arm A (Intensive Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glasdegib + '7+3' Induction(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Intensive Study)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + '7+3' Induction(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Non-intensive study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glasdegib + azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Non-intensive study)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glasdegib</intervention_name>
    <description>Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.&#xD;
Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.&#xD;
Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.</description>
    <arm_group_label>Arm A (Intensive Study)</arm_group_label>
    <other_name>PF-04449913</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin + cytarabine</intervention_name>
    <description>'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).&#xD;
If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');</description>
    <arm_group_label>Arm A (Intensive Study)</arm_group_label>
    <arm_group_label>Arm B (Intensive Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.</description>
    <arm_group_label>Arm A (Non-intensive study)</arm_group_label>
    <arm_group_label>Arm B (Non-intensive study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.&#xD;
Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.</description>
    <arm_group_label>Arm B (Intensive Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.</description>
    <arm_group_label>Arm B (Non-intensive study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glasdegib</intervention_name>
    <description>Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.&#xD;
Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.</description>
    <arm_group_label>Arm A (Non-intensive study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Consolidation with single agent cytarabine 3 g/m2 IV for adults &lt;60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.</description>
    <arm_group_label>Arm A (Intensive Study)</arm_group_label>
    <arm_group_label>Arm B (Intensive Study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HSCT</intervention_name>
    <description>If required, and done per standard of care post Induction(s).</description>
    <arm_group_label>Arm A (Intensive Study)</arm_group_label>
    <arm_group_label>Arm B (Intensive Study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the Intensive and Non Intensive study (unless where indicated):&#xD;
&#xD;
          1. Subjects with untreated AML according to the World Health Organization (WHO) 2016&#xD;
             Classification2, including those with:&#xD;
&#xD;
               -  AML arising from MDS or another antecedent hematologic disease (AHD).&#xD;
&#xD;
               -  AML after previous cytotoxic therapy or radiation (secondary AML).&#xD;
&#xD;
          2. 18 years of age (In Japan, 20 years of age).&#xD;
&#xD;
          3. Adequate Organ Function as defined by the following:&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) 3&#xD;
                  x upper limit of normal (ULN), excluding subjects with liver function&#xD;
                  abnormalities due to underlying malignancy.&#xD;
&#xD;
               -  Total serum bilirubin 2 x ULN (except subjects with documented Gilbert's&#xD;
                  syndrome).&#xD;
&#xD;
               -  Estimated creatinine clearance 30 mL/min as calculated using the standard method&#xD;
                  for the institution.&#xD;
&#xD;
          4. QTc interval 470 msec using the Fridericia correction (QTcF).&#xD;
&#xD;
          5. All anti cancer treatments (unless specified) should be discontinued 2 weeks from&#xD;
             study entry, for example: targeted chemotherapy, radiotherapy, investigational agents,&#xD;
             hormones, anagrelide or cytokines.&#xD;
&#xD;
               -  For control of rapidly progressing leukemia, all trans retinoic acid (ATRA),&#xD;
                  hydroxyurea, and/or leukopheresis may be used before and for up to 1 week after&#xD;
                  the first dose of glasdegib.&#xD;
&#xD;
          6. Serum or urine pregnancy test (for female subjects of childbearing potential) with a&#xD;
             minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin&#xD;
             (hCG) negative at screening.&#xD;
&#xD;
          7. Male and female subjects of childbearing potential and at risk for pregnancy must&#xD;
             agree to use at least one highly effective method of contraception throughout the&#xD;
             study and for 180 days after the last dose of azacitidine, cytarabine, or&#xD;
             daunorubicin; and the last dose of glasdegib or placebo, whichever occurs later.&#xD;
&#xD;
          8. Female subjects of non childbearing potential must meet at least 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Have undergone a documented hysterectomy and/or bilateral oophorectomy;&#xD;
&#xD;
               2. Have medically confirmed ovarian failure; or&#xD;
&#xD;
               3. Achieved postmenopausal status, defined as follows: cessation of regular menses&#xD;
                  for at least 12 consecutive months with no alternative pathological or&#xD;
                  physiological cause; status may be confirmed by having a serum follicle&#xD;
                  stimulating hormone (FSH) level confirming the postmenopausal state.&#xD;
&#xD;
             All other female subjects (including female subjects with tubal ligations) are&#xD;
             considered to be of childbearing potential.&#xD;
&#xD;
          9. Consent to a saliva sample collection for a germline comparator, unless prohibited by&#xD;
             local regulations or ethics committee (EC) decision.&#xD;
&#xD;
         10. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient has been informed of all pertinent aspects of the study.&#xD;
&#xD;
         11. Subjects who are willing and able to comply with the study scheduled visits, treatment&#xD;
             plans, laboratory tests and other procedures (including bone marrow [BM] assessments).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with any of the following characteristics/conditions will not be included in the&#xD;
        study:&#xD;
&#xD;
          1. Acute Promyelocytic Leukemia (APL) and APLwith PML RARA, subjects (WHO 2016&#xD;
             classification).&#xD;
&#xD;
          2. AML with BCR ABL1 or t(9;22)(q34;q11.2) as a sole abnormality.&#xD;
&#xD;
               -  Complex genetics may include t(9;22) cytogenetic translocation.&#xD;
&#xD;
          3. Subjects with known active CNS leukemia.&#xD;
&#xD;
          4. Participation in other clinical studies involving other investigational drug(s)&#xD;
             (Phases 1 4) within 4 weeks prior study entry and/or during study participation.&#xD;
&#xD;
          5. Subjects known to be refractory to platelet or packed red cell transfusions per&#xD;
             Institutional Guidelines, or a patient who refuses blood product support.&#xD;
&#xD;
          6. Subjects with another active malignancy on treatment with the exception of basal cell&#xD;
             carcinoma, non melanoma skin cancer, cervical carcinoma in situ. Other prior or&#xD;
             concurrent malignancies will be considered on a case by case basis.&#xD;
&#xD;
          7. Any one of the following ongoing or in the previous 6 months: myocardial infarction,&#xD;
             congenital long QT syndrome, Torsades de pointes, symptomatic arrhythmias (including&#xD;
             sustained ventricular tachyarrhythmia), right or left bundle branch block and&#xD;
             bifascicular block, unstable angina, coronary/peripheral artery bypass graft,&#xD;
             symptomatic congestive heart failure (CHF New York Heart Association class III or IV),&#xD;
             cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism;&#xD;
             as well as bradycardia defined as &lt;50 bpms.&#xD;
&#xD;
          8. Subjects with an active, life threatening or clinically significant uncontrolled&#xD;
             systemic infection not related to AML.&#xD;
&#xD;
          9. Subjects with left ventricular ejection fraction (LVEF) &lt;50% are excluded from the&#xD;
             Intensive Chemotherapy Study only.&#xD;
&#xD;
         10. Cumulative anthracycline dose equivalent of 550 mg/m2 of daunorubicin for the&#xD;
             Intensive Chemotherapy Study only.&#xD;
&#xD;
         11. Known malabsorption syndrome or other condition that may significantly impair&#xD;
             absorption of study medication in the investigator's judgment (eg, gastrectomy, lap&#xD;
             band, Crohn's disease) and inability or unwillingness to swallow tablets or capsules.&#xD;
&#xD;
         12. Current use or anticipated requirement for drugs that are known strong CYP3A4/5&#xD;
             inducers.&#xD;
&#xD;
         13. Concurrent administration of herbal preparations.&#xD;
&#xD;
         14. Major surgery or radiation within 4 weeks of starting study treatment.&#xD;
&#xD;
         15. Documented or suspected hypersensitivity to any one of the following:&#xD;
&#xD;
               -  For subjects assigned to intensive chemotherapy, documented or suspected&#xD;
                  hypersensitivity to cytarabine (not including drug fever or exanthema, including&#xD;
                  known cerebellar side effects) or daunorubicin.&#xD;
&#xD;
               -  For subjects assigned to non intensive chemotherapy, documented or suspected&#xD;
                  hypersensitivity to azacitidine or mannitol.&#xD;
&#xD;
         16. Known active drug or alcohol abuse.&#xD;
&#xD;
         17. Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study.&#xD;
&#xD;
         18. Pregnant females or breastfeeding female subjects.&#xD;
&#xD;
         19. Known recent or active suicidal ideation or behavior.&#xD;
&#xD;
         20. Investigator site staff members directly involved in the conduct of the study and&#xD;
             their family members, site staff members otherwise supervised by the investigator, or&#xD;
             subjects who are Pfizer employees, including their family members, directly involved&#xD;
             in the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Department of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Drug Information/Investigational Drugs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Ronald Reagan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Westlake Village</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmerica Division, Inc., c/o Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health/Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriStar Bone Marrow Transplant</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Cancer and Stem Cell Transplant Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg, Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende av</name>
      <address>
        <city>Brugge</city>
        <zip>B-8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Brussel (UZ Brussel)</name>
      <address>
        <city>Brussels</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'Ile-de- Montréal - Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC, Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Second Provincial General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510317</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Yanda Lu Daopei Hospital</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <zip>065201</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital/Hematology Department</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology/Cancer Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interni hematologicka a onkologicka klinika, Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnicni lekarna</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ustavni lekarna</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika hematoonkologie</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interní hematologická klinika, Fakultni nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ústavni lékárna</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes Hotel Dieu</name>
      <address>
        <city>Nantes cedex</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud - Service d'Hematologie</name>
      <address>
        <city>Pierre-Benite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universitaet Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hesse</state>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Koeln</city>
        <state>North Rhine Westphalia</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Megyei Oktató Kórház, II. Belgyógyászat- Hematológiai Osztály</name>
      <address>
        <city>Győr</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Korhaz, Hematologia</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Korhaz,</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center (Ein Kerem)</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemato-oncology ambulatory Service</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi, Clinica Di Ematologia</name>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Ancona</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOD Farmacia-Dipt dei servizi -AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi</name>
      <address>
        <city>Torette Di Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Ferrara- Arcispedale Sant'Anna,</name>
      <address>
        <city>Cona, Ferrara</city>
        <state>FE</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro -</name>
      <address>
        <city>Pesaro</city>
        <state>PU</state>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese.</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Bologna Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daini Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka-City</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka-Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Disaster Medical Center</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Center, Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología</name>
      <address>
        <city>México</city>
        <state>MÉX</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WWCOiT im. M. Kopernika w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic 'Prof. Dr. Ion Chiricuta'</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400124</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal Filantropia Craiova, Sectia Clinica Hematologie</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sp. Clinic de Urgenta Militar Central Dr. Carol Davila</name>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Coltea, Clinica de Hematologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI NNR NN RCH n. a. N.A. Semashko</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Ryazan Region 'Regional Clinical Hospital' (SBI RR RCH)</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI RusSRHTI FMBA of Russia</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.A Almazov NMRC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Orebro</name>
      <address>
        <city>Orebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>WEST Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1371019</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <results_first_submitted>June 2, 2021</results_first_submitted>
  <results_first_submitted_qc>June 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glasdegib;</keyword>
  <keyword>untreated;</keyword>
  <keyword>Hedgehog Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03416179/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03416179/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated glasdegib in intensive and non-intensive chemotherapy populations. Intensive study: Glasdegib was studied in combination with cytarabine and daunorubicin for the treatment of adult participants with previously untreated acute myeloid leukemia (AML). Non-intensive study: Glasdegib was studied in combination with azacitidine for the treatment of adult participants with previously untreated AML who were not candidates for intensive induction chemotherapy.</recruitment_details>
      <pre_assignment_details>Results are reported at primary completion date and data has been reported only for primary outcome measures. Data for secondary outcome measures would be posted at secondary completion date. Inadvertently 1 participant was enrolled twice into the study resulting in enrollment number as 730. However, a total of 729 participants were randomized and received treatment in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intensive Study: Glasdegib + Cytarabine + Daunorubicin</title>
          <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 milligram per square meter (mg/m^2) daily by intravenous (IV) infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with less than (&lt;) 5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram per square meter (gm/m^2) IV for adults greater than or equals to (&gt;=) 60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received hematopoietic stem cell transplantation (HSCT) per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 milligram (mg) tablet orally (PO) once daily (QD) from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive complete remission (CR) minimal residual disease (MRD)-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
        </group>
        <group group_id="P2">
          <title>Intensive Study: Placebo + Cytarabine + Daunorubicin</title>
          <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 mg/m^2 daily by IV infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with &lt;5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram/m^2 IV for adults &gt;=60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received HSCT per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 mg matching placebo tablet PO QD from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive CR MRD-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
        </group>
        <group group_id="P3">
          <title>Non-intensive Study: Glasdegib + Azacitidine</title>
          <description>Participants received chemotherapy with azacitidine 75 mg/m^2 subcutaneous (SC) injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participant refusal or death, whichever occurred first. Participants also were to receive glasdegib 100 mg PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
        </group>
        <group group_id="P4">
          <title>Non-intensive Study: Placebo + Azacitidine</title>
          <description>Participants received chemotherapy with azacitidine 75 mg/m^2 SC injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participants refusal or death, whichever occurred first. Participants also received glasdegib 100 mg tablet matching placebo PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib matching placebo up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="163"/>
                <participants group_id="P4" count="162"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis (FA) set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Intensive Study: Glasdegib + Cytarabine + Daunorubicin</title>
          <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 milligram per square meter (mg/m^2) daily by intravenous (IV) infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with less than (&lt;) 5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram per square meter (gm/m^2) IV for adults greater than or equals to (&gt;=) 60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received hematopoietic stem cell transplantation (HSCT) per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 milligram (mg) tablet orally (PO) once daily (QD) from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive complete remission (CR) minimal residual disease (MRD)-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
        </group>
        <group group_id="B2">
          <title>Intensive Study: Placebo + Cytarabine + Daunorubicin</title>
          <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 mg/m^2 daily by IV infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with &lt;5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram/m^2 IV for adults &gt;=60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received HSCT per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 mg matching placebo tablet PO QD from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive CR MRD-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
        </group>
        <group group_id="B3">
          <title>Non-intensive Study: Glasdegib + Azacitidine</title>
          <description>Participants received chemotherapy with azacitidine 75 mg/m^2 subcutaneous (SC) injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participant refusal or death, whichever occurred first. Participants also were to receive glasdegib 100 mg PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
        </group>
        <group group_id="B4">
          <title>Non-intensive Study: Placebo + Azacitidine</title>
          <description>Participants received chemotherapy with azacitidine 75 mg/m^2 SC injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participants refusal or death, whichever occurred first. Participants also received glasdegib 100 mg tablet matching placebo PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib matching placebo up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="163"/>
            <count group_id="B4" value="162"/>
            <count group_id="B5" value="729"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.55" spread="12.60"/>
                    <measurement group_id="B2" value="55.38" spread="13.61"/>
                    <measurement group_id="B3" value="73.19" spread="7.17"/>
                    <measurement group_id="B4" value="73.14" spread="6.82"/>
                    <measurement group_id="B5" value="63.63" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="354"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="139"/>
                    <measurement group_id="B5" value="616"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="429"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intensive Study: Overall Survival (OS)</title>
        <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.</description>
        <time_frame>Baseline up to 25 months</time_frame>
        <population>FA set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Study: Glasdegib + Cytarabine + Daunorubicin</title>
            <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 milligram per square meter (mg/m^2) daily by intravenous (IV) infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with less than (&lt;) 5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram per square meter (gm/m^2) IV for adults greater than or equals to (&gt;=) 60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received hematopoietic stem cell transplantation (HSCT) per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 milligram (mg) tablet orally (PO) once daily (QD) from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive complete remission (CR) minimal residual disease (MRD)-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Study: Placebo + Cytarabine + Daunorubicin</title>
            <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 mg/m^2 daily by IV infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with &lt;5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram/m^2 IV for adults &gt;=60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received HSCT per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 mg matching placebo tablet PO QD from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive CR MRD-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Study: Overall Survival (OS)</title>
          <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.</description>
          <population>FA set included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="15.2" upper_limit="18.5"/>
                    <measurement group_id="O2" value="20.4" lower_limit="17.6" upper_limit="NA">Upper limit of 95 % CI was not estimable due to low number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio based on Cox proportional hazards model; under proportional hazards, hazard ratio less than (&lt;) 1 indicated a reduction in hazard rate in favor of Glasdegib 100 mg PO + Cytarabine 100 mg/m^2 IV + Daunorubicin 60 mg/m^2 compared to Placebo + Cytarabine 100 mg/m^2 IV + Daunorubicin 60 mg/m^2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6579</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.755</ci_lower_limit>
            <ci_upper_limit>1.532</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-intensive Study: Overall Survival (OS)</title>
        <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.</description>
        <time_frame>Baseline up to 25 months</time_frame>
        <population>FA set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-intensive Study: Glasdegib + Azacitidine</title>
            <description>Participants received chemotherapy with azacitidine 75 mg/m^2 subcutaneous (SC) injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participant refusal or death, whichever occurred first. Participants also were to receive glasdegib 100 mg PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Non-intensive Study: Placebo + Azacitidine</title>
            <description>Participants received chemotherapy with azacitidine 75 mg/m^2 SC injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participants refusal or death, whichever occurred first. Participants also received glasdegib 100 mg tablet matching placebo PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib matching placebo up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-intensive Study: Overall Survival (OS)</title>
          <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.</description>
          <population>FA set included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="7.7" upper_limit="12.4"/>
                    <measurement group_id="O2" value="10.6" lower_limit="8.4" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio based on Cox proportional hazards model; under proportional hazards, hazard ratio &lt; 1 indicated a reduction in hazard rate in favor of Glasdegib 100 mg PO QD + Azacitidine compared to Placebo + Azacitidine</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5955</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.775</ci_lower_limit>
            <ci_upper_limit>1.388</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (DASI-AML/MDS) Questionnaire</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (DASI-AML/MDS) Questionnaire</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Percentage of Participants With Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Percentage of Participants With Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Percentage of Participants With Complete Remission (CR) Including Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Complete Remission With Negative Minimal Residual Disease (CRMRD-neg)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Percentage of Participants With Partial Remission (PR)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Percentage of Participants With Partial Remission (PR)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Duration of Response</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Duration of Response</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Time to Response</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Event-free Survival</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Event-free Survival</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Participants Global Impression of Symptoms (PGIS)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Participants Global Impression of Symptoms (PGIS)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Participants Global Impression of Change (PGIC)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Participants Global Impression of Change (PGIC)</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Number of Participants With Laboratory Abnormalities Graded by NCI CTCAE v.4.03</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Number of Participants With Laboratory Abnormalities Graded by NCI CTCAE v.4.03</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib</title>
        <time_frame>1 and 4 hour post dose on Day 1 in first induction therapy; pre-dose, 1, and 4 hours post dose on day 1 in consolidation phase cycles 1 and 2</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib</title>
        <time_frame>Pre-dose, 1 and 4 hour post dose on Day 1 and 15 of cycle 1; pre-dose, 1 and 4 hour post dose on day 1 of cycle 2 and 3</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Study: QTc Interval</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-intensive Study: QTc Interval</title>
        <time_frame>Baseline up to 5 years</time_frame>
        <posting_date>12/2023</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 28 days from last dose of study drug (up to 25 months)</time_frame>
      <desc>Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Safety analysis (SA) set included all subjects who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intensive Study: Glasdegib + Cytarabine + Daunorubicin</title>
          <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 milligram per square meter (mg/m^2) daily by intravenous (IV) infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with less than (&lt;) 5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram per square meter (gm/m^2) IV for adults greater than or equals to (&gt;=) 60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received hematopoietic stem cell transplantation (HSCT) per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 milligram (mg) tablet orally (PO) once daily (QD) from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive complete remission (CR) minimal residual disease (MRD)-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Intensive Study: Placebo + Cytarabine + Daunorubicin</title>
          <description>Participants received first induction therapy (28 days) (backbone chemotherapy+experimental therapy). Backbone chemotherapy: Cytarabine 100 mg/m^2 daily by IV infusion for 7 days along with daunorubicin 60 mg/m^2 daily IV for 3 days. Depending upon bone marrow blast or investigator judgement participants had second induction i.e. received either same backbone therapy or cytarabine 100 mg/m^2 IV daily for 5 days and daunorubicin 60 mg/m^2 IV daily for 2 days. Participants with &lt;5% bone marrow blasts entered into consolation phase- treated with either or both of following: 1) cytarabine 1 to 3 gram/m^2 IV for adults &gt;=60 to &lt;60 years twice daily on Days 1, 3, and 5 for 4 cycle (each cycle 28 day) or cytarabine per local prescribing information. 2) Received HSCT per local standard of care. Experimental Therapy: Participants were to receive Glasdegib 100 mg matching placebo tablet PO QD from Day 1 of chemotherapy up to 28 days in both induction and up to 2 years post randomization or until 2 consecutive CR MRD-negative central laboratory results, whichever came first. Participants were to be followed up for first 2 years from last dose and were to had long term survival follow-up for up to 5 years from randomization of last participant or until death/consent withdrawal.</description>
        </group>
        <group group_id="E3">
          <title>Non-intensive Study: Glasdegib + Azacitidine</title>
          <description>Participants received chemotherapy with azacitidine 75 mg/m^2 subcutaneous (SC) injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participant refusal or death, whichever occurred first. Participants also were to receive glasdegib 100 mg PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
        </group>
        <group group_id="E4">
          <title>Non-intensive Study: Placebo + Azacitidine</title>
          <description>Participants received chemotherapy with azacitidine 75 mg/m^2 SC injection or IV infusion from Day 1 up to Day 7 of each cycle (28 day) and continued for at least 6 cycles or until unacceptable toxicity, participants refusal or death, whichever occurred first. Participants also received glasdegib 100 mg tablet matching placebo PO QD from Day 1 of chemotherapy until clinical benefit or disease progression, unacceptable toxicity, consent withdrawal, or death, whichever occurred first. Eligible participants underwent HSCT per local standard of care and were to receive glasdegib matching placebo up to 2 years following randomization unless 2 consecutive negative MRD assessments. Participants were to be followed up for first 2 years from last dose of drug and were to had long term follow-up for survival for up to 5 years from randomization of last participant in study, or until death, or consent withdrawal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Splenic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Clostridial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Clostridium bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Device related bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Disseminated varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Herpes dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Suspected COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Systemic mycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Electroencephalogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>SARS-CoV-2 test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Differentiation syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="195" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="149" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

